Biovie Inc (BIVI) - News Archive

BioVie Inc. a clinical-stage company engaged in the development of transformative therapies for neurological disorders, has recently announced the full funding of its upcoming clinical trial, designated PD-202. This stu...

BioVie Inc. Launches $3.2 Million Stock Offering to Fuel Development of Innovative Therapies OverviewOn October 28, 2024, BioVie Inc. (NASDAQ: BIVI), a clinical-stage biopharmaceutical company focusing on innovative tre...

On October 24, 2024, BioVie Inc. (NASDAQ: BIVI), a clinical-stage biotechnology company headquartered in Carson City, Nevada, announced the successful closing of its registered direct offering of 2,667,000 shares of com...

In the ever-evolving landscape of healthcare, emerging companies like BioVie Inc. find themselves on a precarious tightrope, balancing innovative aspirations against stark financial realities. Recently, BioVie (Nasdaq:...

BioVie Inc. Executes Strategic Securities Offerings Amidst Market Volatility, Aiming for Financial Stability and GrowthCARSON CITY, Nev. In a notable series of strategic financial maneuvers amidst the challenging landsc...

BioVie Inc.: A Steady Ascent in the World of Innovative Drug TherapiesCARSON CITY, Nev. In a significant step forward for a company dedicated to addressing chronic debilitating conditions, BioVie Inc. (Nasdaq: BIVI) has...

BioVie Inc. Announces Pricing of Public Offering: A Strategic Step Towards Revolutionizing Treatment for Chronic Diseases Amid Financial ChallengesIn recent developments, BioVie Inc. (NASDAQ: BIVI), a clinical-stage ent...

BioVie Inc. Pursues Growth Amidst Financial Challenges and Promising Clinical DevelopmentsIn an intricate dance of opportunity and risk, BioVie Inc. (NASDAQ: BIVI) finds itself at a pivotal moment in its journey as a cl...

In a significant development for the pharmaceutical landscape, BioVie, a clinical-stage company focused on advancing innovative therapies, has recently announced the successful acquisition of all necessary scientific ap...

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter tri...

BioVie, a biopharmaceutical company known for its innovative approaches to treating neurodegenerative conditions, has recently announced promising clinical data suggesting that its lead compound, Bezisterim (NE3107), ha...

: In a significant step towards addressing the complexities of Parkinson’s Disease (PD), BioVie has announced an alignment with the FDA regarding a pivotal clinical trial aimed at assessing the efficacy of Bezisterim (N...

BioVie Inc. Unveils Protocol Design for SUNRISE-PD Phase 2 Trial of Bezisterim in Early Parkinson’s Disease at ATMRD 2024BioVie Inc. has made significant strides in the treatment of Parkinson’s disease with its recent a...

Exploring the Potential of Bezisterim in Early Parkinson s Disease and Long COVID: BioVie s Innovative Approach BioVie Inc., a biopharmaceutical company, has been at the forefront of developing novel therapies for chall...

The Formation of Advisory Board and Financial Struggles: Assessing the Impact on BioVie Inc s Long COVID TrialBioVie Inc, a prominent pharmaceutical company, has recently announced the formation of an Advisory Board to...

BioVie s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson s Disease PatientsFull Dataset from Phase 2a trial in Parkinson s Disease suggest patients treated with be...

In recent years, there has been a surge in research exploring innovative therapeutic options for various debilitating diseases. The articles mentioned above shed light on the groundbreaking potential of Bezisterim (NE31...

In recent developments, renowned law firm Hagens Berman has issued an alert to BioVie Inc. (NASDAQ: BIVI) investors who have experienced significant financial losses. The firm urges affected investors to come forward an...

BioVie, a leading pharmaceutical company focused on developing innovative therapies for life-threatening neurological diseases, has made significant strides in its pipeline progress. With a recent financing, the company...

BioVie Inc., a clinical-stage company focused on developing innovative drug therapies for chronic debilitating conditions, including liver disease and neurological disorders, recently announced the pricing of its public...